A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS (Telmisartan) 80 mg Versus COZAAR (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Trial Profile

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare MICARDIS (Telmisartan) 80 mg Versus COZAAR (Losartan) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs Losartan; Telmisartan
  • Indications Diabetic nephropathies; Hypertension
  • Focus Therapeutic Use
  • Acronyms AMADEO
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Mar 2008 Status changed from in progress to completed.
    • 22 May 2007 Results data have been reported.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top